We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study.
- Authors
Smith, C H; Jackson, K; Bashir, S J; Perez, A; Chew, A L; Powell, A M; Wain, M; Barker, J N W N
- Abstract
Infliximab, a mouse-human chimeric monoclonal antibody directed against tumour necrosis factor-alpha, has been shown to be effective for moderate to severe psoriasis, but there are few data published on its use in recalcitrant, treatment-resistant disease or in combination with other antipsoriatic therapies.
- Publication
The British journal of dermatology, 2006, Vol 155, Issue 1, p160
- ISSN
0007-0963
- Publication type
Journal Article
- DOI
10.1111/j.1365-2133.2006.07316.x